Fighting the FDA’s Final Rule on LDTs
CEO Laurie Menser discusses the Association for Molecular Pathology’s court case against the FDA’s rule on laboratory-developed tests.
Top of the News-lir
Subscribe today for access to
Articles and Reports
Getting Started with the FDA’s New LDT Rule
Experts explain what the phase-in process will look like—and how labs can get ahead of the game.
Transitioning the Clinical Lab
What clinical laboratory professionals need to know about healthcare provision for transgender and nonbinary patients
ASCP Agreement with G2 Broadens Member Access to Quality Pathology and Diagnostics Content
...
This content is for Paid Members only.
Register
Register
Already a member? Log in here
6 Steps to Data-Driven Transformation
By Nir Kaldero bio
We're now well into the Fourth Industrial Revolution. The First Industrial Revolution was about steam and railroads, the Second about electricity, and the…
Latest Legal Challenge to ACA May Mean a Hot Mess for Insurance Markets
From - Laboratory Industry Report
After a series of setbacks, Republicans challenging the constitutionality of the Affordable Care Act (ACA) and its individual mandate are…
Industry Buzz: LabCorp and Quest Swept Up in Insurance Contract Partner Swap
From - Laboratory Industry Report
Can you imagine Scarlett and Rhett swapping partners with Romeo and Juliet? Something like the laboratory industry equivalent of that scenario took place on…
Top of the News: ANDE Rapid DNA Platform First to Win FBI Approval
From - Laboratory Industry Report
"Great news! The FBI just called."
–Extremely rare phrase almost never uttered except sarcastically…
New Laws: Congress Doubles Penalties for Medicare Fraud & Abuse
...
This content is for Paid Members only.
Register
Register
Already a member? Log in here
By the Numbers: Spike in M.D. Practice Acquisitions Drives Up Costs of Hospital Care
From - Laboratory Industry Report
Hospitals are gobbling up M.D. practices at a record rate. In addition to endangering the independent physician practice, this trend is driving up the costs of…
Diagnostic danger in the lab: Time to reform how we process orders
Recent report examining 10,000 claims to understand the key drivers of medical malpractice suits found 52 percent involved lab-related errors.
Theranos & Its CEO Settle Stock Fraud Charges with SEC
...
This content is for Paid Members only.
Register
Register
Already a member? Log in here
Emerging Tests: Medicare to Cover Next Gen-Sequencing Tests for Advanced Cancer
From - Laboratory Industry Report
In the PAMA era, there are two salient trends in Medicare Part B lab reimbursements…